|
gptkbp:instanceOf
|
antiretroviral therapy
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
J05AG01
|
|
gptkbp:bioavailability
|
>90%
|
|
gptkbp:brand
|
gptkb:Viramune
|
|
gptkbp:CASNumber
|
129618-40-2
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugInteraction
|
gptkb:rifampicin
gptkb:ketoconazole
oral contraceptives
|
|
gptkbp:eliminationHalfLife
|
25-30 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C15H14N4O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nevirapine
|
|
gptkbp:KEGGID
|
D08210
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:MedlinePlusID
|
a696005
|
|
gptkbp:MeSH_ID
|
gptkb:D019962
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
60%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL411
gptkb:DB00238
4307
4463
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fever
nausea
rash
hepatotoxicity
|
|
gptkbp:synonym
|
gptkb:NVP
gptkb:Viramune
|
|
gptkbp:UNII
|
99DK7FVK1H
|
|
gptkbp:usedFor
|
HIV-1 infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:NVP
|
|
gptkbp:bfsLayer
|
6
|